Residual FDG-PET metabolic activity in metastatic melanoma patients with prolonged response to anti-PD-1 therapy

Benjamin Y. Kong, Alexander M. Menzies, Catherine A B Saunders, Elizabeth Liniker, Sangeetha Ramanujam, Alex Guminski, Richard F. Kefford, Georgina V. Long, Matteo S. Carlino*

*Corresponding author for this work

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

18-Fluorodeoxyglucose positron emission tomography (FDG-PET) scans were performed on 27 patients with unresectable stage IIIC or IV melanoma after prolonged treatment with anti-PD-1 antibodies to examine the hypothesis that patients with prolonged response to treatment may have metabolically inactive lesions by FDG-PET. Scans were performed at a median of 15.2 months (range 12–29 months) after starting treatment. Overall, 15 of 27 (56%) patients had a positive FDG-PET scan. Eight patients with positive scans underwent biopsy; 5 of 8 (62%) were melanoma and 3 of 8 (38%) were immune cell infiltrates. Of the 12 patients with negative FDG-PET scans, six had residual computerized tomography-visible lesions, five have ceased treatment, and none have recurred with follow-up of 6–10 months. Patients with residual metastases after a prolonged period without progression on anti-PD-1 therapy may have metabolically inactive lesions. Isolated metabolically active lesions in clinically well patients may reveal immune cell infiltrates rather than melanoma.

Original languageEnglish
Pages (from-to)572-577
Number of pages6
JournalPigment Cell and Melanoma Research
Volume29
Issue number5
DOIs
Publication statusPublished - 1 Sep 2016

    Fingerprint

Cite this

Kong, B. Y., Menzies, A. M., Saunders, C. A. B., Liniker, E., Ramanujam, S., Guminski, A., ... Carlino, M. S. (2016). Residual FDG-PET metabolic activity in metastatic melanoma patients with prolonged response to anti-PD-1 therapy. Pigment Cell and Melanoma Research, 29(5), 572-577. https://doi.org/10.1111/pcmr.12503